Loading
A 2025 letter recording the latest changes to Europe's continuously updated guideline for metastatic breast cancer, the mechanism through which first-line antibody-drug conjugate results enter European practice.
Letter in Annals of Oncology (2025) by Trapani, Martins-Branco, Curigliano, Gennari and colleagues announcing updated systemic treatment recommendations from the ESMO Metastatic Breast Cancer Living Guideline. Europe PMC indexes no abstract, so OnCo carries no figures from it; the current recommendations are read from the living guideline on the ESMO website, which for triple-negative disease incorporates the first-line antibody-drug conjugate trials as they are published.
For a fast-moving disease the living guideline, not the 2021 paper, is where European recommendations for triple-negative breast cancer now change; readers should check the website rather than the journal.
Shares Giuseppe Curigliano, Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares European Society for Medical Oncology (ESMO), Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Giuseppe Curigliano, Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.